Therefore, the TUG1/IGF2BP2/miR-195-5p axis intensify CRC cell growth and induce such malignant cell resistance to cisplatin, regarding as underlying target for CRC therapy [73]. This evidence concerns the gene TUG1 and colorectal carcinoma.